Spinal Muscular Atrophy Treatment Market Expected to Reach USD 34.8 Billion by 2032

The Global Spinal Muscular Atrophy (SMA) Treatments Market was valued at USD 7.3 billion in 2023 and is forecast to grow at a CAGR of 19.1% from 2024 to 2032. Key growth factors include the expansion of newborn screening programs, which enable earlier diagnoses and expand treatment eligibility. Early detection improves patient outcomes and drives demand for neurological treatments.

According to Health Union, LLC, SMA affects approximately 1 in every 6,000 to 10,000 newborns globally, with Type 1 SMA being the most severe and accounting for over half of all cases. Currently, around 25,000 Americans live with SMA. Advancements in diagnostic technologies and increased awareness among healthcare providers and patients are expected to further propel market growth.

The SMA treatment market is segmented based on type, treatment type, route of administration, and region.

The market is divided into categories such as infant SMA, Werdnig-Hoffmann disease, adult SMA, and Kugelberg-Welander disease. The Werdnig-Hoffmann disease segment led the market in 2023, generating USD 2.9 billion in revenue. Mandatory newborn screenings have enabled early detection, allowing for timely treatment, which is most effective before significant motor neuron loss occurs. This trend is expected to continue driving market expansion. Research and development, along with pharmaceutical collaborations aimed at reducing treatment costs, have also expanded patient access, fueling market growth. Early access or compassionate use programs for SMA Type 1 treatments are further boosting market momentum.

The treatment market is categorized into medication, supportive care, and spinal surgery. The medication segment, which includes antisense oligonucleotides, gene therapy, and other drugs, dominated with a 64.2% share in 2023. Breakthrough drugs such as Spinraza (Nusinersen) and Evrysdi (Risdiplam) have revolutionized SMA treatment by targeting the genetic root cause and promoting SMN protein production, which has driven market growth. The availability of both injectable and oral formulations has enhanced treatment accessibility, catering to a variety of patient needs and preferences, further stimulating market growth.

In 2023, North America, particularly the U.S., accounted for a substantial 45.6% share of the global SMA treatment market, and it is expected to retain this dominance. Key drivers of growth in the region include supportive policies for rare diseases, advanced healthcare infrastructure, and ongoing clinical trials. The presence of major pharmaceutical companies and increased funding for research and development also support market expansion. Additionally, rising awareness and early diagnosis of SMA are contributing to the growth of the treatment market.

Source: https://www.gminsights.com/industry-analysis/spinal-muscular-atrophy-treatment-market